WB: Approx. 140 kDa band observed in human ovary lysates (calculated MW of 146 kDa band according to NP_660333.2). An additional band of unknown identity was also consistently observed at 33 kDa. This band was successfully blocked by incubation with the immunizing peptide. GPR125 antibody also validated for IHC-P from a verified customer review.
146 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 1 Review rated 4 using NBP1-03561 in the following applications:
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
0.02% Sodium Azide
Immunogen affinity purified
Alternate Names for GPR125 Antibody
G protein-coupled receptor 125
probable G-protein coupled receptor 125
GPR125 is an orphan receptor which has a leucine rich repeat (LRR), an immunoglobulin (Ig) domain, and a hormone-binding domain (HBD). The Ig domain shows similarities to motilin andtitin, while the LRR domain shows similarities to LRIG1 and SLIT1-2. ESTs have been isolated primarily from amnion,connective tissue, ear, embryo, eye,ganglion, heart, lung,placenta, and skin libraries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.